ALK and non-small cell lung carcinoma: The ORR for alectinib was 82.9%, whereas the ORR for crizotinib was 75.5%.46,47 Adding to a real-world study conducted in Japan assessing the effectiveness and safety of alectinib in patients with ALK-positive NSCLC who were previously exposed to crizotinib.